BioXcel scores another win with reformulated Pfizer sedative, this time in an Alzheimer's symptom
Less than six months after reporting positive Phase III results for its lead program in treating agitation related to schizophrenia and bipolar disorder, small AI biotech BioXcel followed up Tuesday with top-line data in an early stage trial for agitation in dementia and Alzheimer’s disease.
The experimental drug, known as BXCL501, met its primary and secondary endpoints in the higher evaluable dose of a 54-patient Phase Ib/II trial, BioXcel announced, inducing a statistically significant calming effect compared to placebo with no severe or serious side effects. With the data in hand, BioXcel plans to meet with the FDA sometime in the first half of 2021 before launching a late-stage study sometime afterwards.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.